BioNTech SE, along with its subsidiaries, develops and commercializes immunotherapies in Germany. It offers BNT162, an mRNA vaccine for SARS-CoV-2. The company also develops oncology drugs in Phase III trials, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide. Additional pipeline candidates include Phase 2/3 drugs such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, and Pumitamig for metastatic colorectal and non-small cell lung cancer. Phase II oncology drugs include BNT116 for advanced non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advanced colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. It also develops BNT166 in Phase II for mpox virus, and Phase 1/2 infectious disease drugs including BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. Incorporated in 2008, BioNTech is headquartered in Mainz, Germany.
Lung cancer win lifts BioNTech, but patent suit and downgrade weigh
▲
Gotistobart nearly doubles lung cancer survival BioNTech and OncoC4 reported that gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial. This is the first strong sign that BioNTech's cancer pipeline can work, which supports the shares because investors have doubted the company's move beyond COVID vaccines.
This is the period's biggest new positive and directly addresses doubts about BioNTech's cancer strategy.
▼
Monsanto mRNA patent lawsuit moves forward A Delaware judge rejected BioNTech's bid to dismiss Monsanto's patent lawsuit over mRNA technology used in COVID-19 vaccines. The case can now proceed, creating legal uncertainty and potential future costs or royalties, which weighs on the shares.
This is a new legal risk that could affect BioNTech's finances and is not in earlier reports.
▼
BMO downgrade and price target cut BMO downgraded BioNTech to market perform and cut its price target to $105 from $128, citing the failed colorectal cancer trial and lower revenue guidance. Analyst downgrades can push the shares down because they signal weaker confidence in future earnings.
This is a new analyst action that directly affects investor sentiment and the stock's perceived value.
▲
Health Canada approves XFG-adapted COMIRNATY Health Canada approved BioNTech and Pfizer's XFG-adapted COVID-19 vaccine for people aged 6 months and older. This secures regulated seasonal revenue from Canada, helping offset weaker overall COVID demand and supporting the balance sheet.
This is a new regulatory approval that adds a revenue stream and is not in earlier reports.
Q3 2026
▼2▲1
BioNTech's cancer pipeline advances but COVID collapse and trial setback weigh
▲
Cancer pipeline progress BioNTech's cancer pipeline gained traction: gotistobart showed strong Phase 3 lung cancer survival data, pumitamig advanced in kidney cancer, and Moderna/Merck's mRNA cancer vaccine success lifted sector sentiment.
This is a key positive driver for the stock, showing pipeline potential.
▼
COVID revenue collapse and guidance cut COVID revenue continues collapsing, forcing restructuring and a 2026 guidance cut to €1.6–1.9 billion, which pressures the company's financial outlook.
This is a major negative factor affecting revenue and investor confidence.
▼
Colorectal cancer trial halted BioNTech's own mRNA colorectal cancer trial was halted for futility and a survival imbalance, cutting shares and raising concerns about its pipeline.
This is a significant setback that directly impacted the stock price.
◆
Legal risks and leadership change Patent lawsuits from Arbutus/Roivant and Monsanto add legal risk, while a new CEO brings execution uncertainty and BMO downgraded the stock.
These factors create uncertainty and negative sentiment, offsetting some positives.
News & notes moving22UA.XETRA
United StatesChinaDenmarkFrance
Biotech & Genomic Medicine▼
Sanofi, Novartis and Novo Nordisk Lead Week of Multi-Billion-Dollar Healthcare Deals
A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech and Moderna to dismiss lawsuits filed by Bayer's Monsanto unit over their use of US Patent No. 7,741,118, a patent related to mRNA technology, with Judge William Bryson saying the companies failed to prove the patent was invalid or not infringed by their COVID-19 vaccines. Sanofi agreed to a deal worth up to $8B, including $1B upfront, with Regeneron to jointly develop four long-acting immunology therapies, led by the clinical-stage IL-13 monoclonal antibody REGN20423. China's Abogen Biosciences signed a licensing and option agreement with Novartis worth up to $7.8B, comprising a $575 million upfront payment and up to approximately $7.2 billion in potential milestone payments if all options on all programs are exercised, covering an exclusive worldwide license to Abogen's lead asset ABO2203. Jiangsu Hengrui Pharmaceuticals agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6B, with $300M upfront and the transaction expected to close in Q4 2026. Meanwhile, the S&P 500 Health Care Sector Index slipped 2.66% for the week, with Incyte down 6.93% and Regeneron down 6.71% among the top decliners, while McKesson rose 4.11% and Cardinal Health gained 3.67%.
Judge Rejects Pfizer, BioNTech, Moderna Bids to Dismiss Monsanto mRNA Patent Suits
A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech, and Moderna to dismiss lawsuits filed against them by Bayer's Monsanto unit over their use of a patent related to mRNA technology. The patent at issue, US Patent No. 7,741,118, covers bolstering mRNA in crops to boost expression of a pest-resistant protein, and Monsanto argued in its suit that the companies used it in their COVID-19 mRNA vaccines to eliminate problem coding sequences in the building blocks of cells to improve mRNA stability and the amount or quality of protein produced. Judge William Bryson said the companies failed to prove that the '118 patent was invalid or not infringed by their vaccines, according to Reuters. Moderna had argued that the patent covers an unpatentable law of nature. Monsanto also has a lawsuit in a New Jersey federal court against Johnson & Johnson involving the same patent.
BAYN.XETRA · Regulation · Positive Bayer's Monsanto unit won the ruling allowing its mRNA patent infringement suits against Pfizer, BioNTech and Moderna to proceed.
BioNTech Wins Health Canada Approval for XFG-Adapted COMIRNATY as Gotistobart Nearly Doubles Survival in Phase 3 Lung Cancer Trial
Pfizer Canada and BioNTech announced Health Canada's approval of the Omicron XFG-adapted COMIRNATY vaccine for individuals aged 6 months and older, aligning with 2026-2027 public health recommendations. A few days earlier, BioNTech and OncoC4 reported that the investigational CTLA-4 antibody gotistobart nearly doubled median overall survival versus chemotherapy in a Phase 3 lung cancer trial stage. The Health Canada authorization, following earlier US and EU XFG approvals in 2026, shows the COVID-19 franchise still contributes regulated, seasonal revenue while BioNTech leans into oncology. BioNTech's narrative projects €2.2 billion revenue and €390.1 million earnings by 2029, implying a 6.0% yearly revenue decline and an earnings increase of about €2.1 billion from -€1.7 billion today, with a $118.06 fair value and 20% upside to its current price. Bullish analysts assume revenue climbs to about €3.0 billion and earnings to €313.1 million by 2029, though the new gotistobart data and oncology execution risks could shift how those upbeat assumptions are weighed against more cautious views.
FDA Approves Pfizer and BioNTech's COMIRNATY XFG COVID-19 Vaccine Formula
Pfizer Inc. and BioNTech SE announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. The approval, based on clinical, real-world, and manufacturing data showing strong immune responses against circulating strains, aligns with FDA strain guidance for fall 2026. For Pfizer, the clearance protects a recurring seasonal revenue stream that supports margins and cash flow while the company funds its non-COVID pipeline and manages upcoming loss-of-exclusivity events. For BioNTech, it validates the execution power of its proprietary mRNA platform and preserves its balance sheet, which carries minimal debt and substantial cash reserves to fund late-stage oncology trials without dilutive financing. Both companies still face long-term market contraction as COVID-19 booster demand has normalized well below pandemic peaks, leaving Pfizer's earnings less predictable against elevated debt and exposing BioNTech's heavy operating losses as vaccine revenues fall short of its massive R&D expenses.
Biotech & Genomic Medicine › mRNA Platforms ▲Regulation
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) Competition
22UA.XETRA · Regulation · Positive FDA approved BioNTech's COMIRNATY XFG formula, validating its mRNA platform and preserving its balance sheet.
PFE · Regulation · Positive FDA approved Pfizer's supplemental BLA for the 2026-2027 COMIRNATY XFG formula, protecting a recurring seasonal revenue stream.
BMO Downgrades BioNTech to Market Perform, Cuts Price Target to $105
BMO Capital Markets downgraded BioNTech SE from outperform to market perform on Sept. 8, 2026, and lowered its 12-month price target for the biotech stock from $128 to $105. The downgrade followed BioNTech's Aug. 28, 2026 announcement that it was canceling a Phase 2 clinical trial of the personalized mRNA cancer vaccine BNT122-01 in colorectal cancer after the therapy failed to show statistically significant efficacy, with no safety concerns cited. BioNTech lowered its full-year revenue guidance to €1.6 billion to €1.9 billion from a previous forecast of €2 billion to €2.3 billion. The company still has more than 25 Phase 2 and Phase 3 clinical studies of experimental cancer therapies underway, and recently reported that gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated patients with squamous non-small cell lung cancer. BioNTech expects data from 11 other late-stage studies by the end of 2029, with results from three due before the end of this year, while its market cap sits near $24 billion and its cash, cash equivalents, and security investments totaled roughly €16.6 billion, or around $19 billion, as of June 30, 2026.
Biotech & Genomic Medicine › mRNA Platforms ▼Technology
Biotech & Genomic Medicine › Oncology Therapeutics Technology
22UA.XETRA · Capital · Negative BMO downgraded BioNTech to market perform and cut its price target to $105 from $128.
22UA.XETRA · Technology · Negative BioNTech canceled its Phase 2 BNT122-01 colorectal cancer vaccine trial after it failed to show statistically significant efficacy.
22UA.XETRA · Demand · Negative BioNTech lowered full-year revenue guidance to €1.6-1.9 billion from €2-2.3 billion.
Moderna Jumps 6% as 137% Month Extends on Melanoma Vaccine Data
Moderna climbed 6% to $154 in morning trading, extending a 137% one-month rally driven by its Phase 2b adjuvant melanoma data showing intismeran autogene plus KEYTRUDA cut the risk of recurrence or death by 49% versus KEYTRUDA alone. No new Moderna announcement, filing, analyst action or trial result landed Thursday to explain the move, and the broader tape offered little help: the iShares Biotechnology ETF rose 1% to $204.5 and the SPDR S&P 500 ETF Trust rose 1% to $763.49. BioNTech, which runs a rival individualized messenger RNA cancer vaccine program with Genentech, edged up just 1% to $97.00, a muted response that suggests the market is paying for Moderna's specific asset rather than the messenger RNA cancer vaccine category as a whole; BioNTech chief medical officer Özlem Türeci has said the company sees no read-through between melanoma and colorectal cancer. Novavax, a vaccine-sector name but not a participant in the messenger RNA cancer vaccine program, rose 2% to $9.5 on what reads as group beta. Merck is Moderna's partner on the individualized neoantigen program, which now spans nine Phase 2/3 trials across melanoma, non-small cell lung cancer, bladder and renal cell carcinoma, and Moderna has guided to an interim analysis from its Phase 3 adjuvant melanoma trial in the second half of 2026, with management saying it is highly confident the interim will be conducted this year. For 2026, Moderna guided to up to 10% revenue growth and year-end cash of $4.7 billion to $5.2 billion, and chief executive Stéphane Bancel has described oncology as a key focus for the second half of 2026; the full dataset from the August readout has not yet been presented publicly, with the oncology congress in Madrid in late October the next scheduled opportunity.
MRNA · Technology · Positive Extends 137% rally on Phase 2b melanoma data showing intismeran autogene plus KEYTRUDA cut recurrence/death risk 49%.
22UA.XETRA · Competition · Neutral Rival mRNA cancer vaccine program edged up only 1%, suggesting market pays for Moderna's specific asset rather than the category.
MRK · · Neutral Named only as Moderna's partner on the individualized neoantigen program; no independent Merck development in the article.
BioNTech Lung Cancer Data Shows Gotistobart Nearly Doubled Survival
BioNTech reported detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. The shares traded around US$96.69, with a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. BioNTech now trades at roughly a 22% discount to analyst targets, with the most followed fair value view at $120.62 against the last close of $96.69. The company's pipeline includes multiple late stage Phase II and III trials for BNT327 and mRNA cancer immunotherapies in lung and breast cancers, supported by the planned CureVac acquisition. Risks to the bullish case include late stage oncology trial failures and prolonged COVID-19 vaccine demand weakness and related litigation.
BioNTech's gotistobart nearly doubles lung cancer survival in Phase 3 trial
BioNTech SE reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need. The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46; median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, which remains the critical test for registration and broader investor confidence, and the company says it has 14 ongoing pivotal trials and more than 10 novel combination programs, with its lung-cancer strategy spanning more than 16 ongoing clinical trials and five Phase 3 programs. BioNTech had €16.6 billion in cash, cash equivalents, and securities at June 30, 2026, despite spending €1.0 billion on adjusted R&D during the first half, while first-half 2026 revenue fell to €223.7 million from €443.6 million a year earlier and the company expects 2026 revenue of only €1.6 billion to €1.9 billion.
BioNTech Ends Colorectal Cancer Vaccine Trial After Survival Imbalance
BioNTech SE is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, in colorectal cancer after an independent monitoring committee concluded that continuing the trial was unlikely to demonstrate effectiveness. The committee also identified a numerical imbalance in overall survival between study groups, though the magnitude and cause were not disclosed. This setback raises questions about BioNTech's broader mRNA cancer vaccine strategy, particularly in "cold" tumors like colorectal and pancreatic cancer that have historically responded poorly to immunotherapy. The company said the decision will not affect its separate pancreatic cancer trial, which combines the vaccine with Roche's Tecentriq and has data expected in 2031. BioNTech's shares fell 7.5% following the announcement, contrasting with a recent 20% gain after Merck and Moderna reported positive melanoma results for their personalized mRNA vaccine. The company is also developing BNT113 for head and neck cancer, with interim data expected later this year, and is shifting toward antibody-drug conjugates and bispecific therapies like pumitamig.
RFK Jr. probes whether U.S. troops died from COVID vaccines
Health Secretary Robert F. Kennedy Jr. and Defense Secretary Pete Hegseth are investigating whether U.S. troops died from COVID-19 vaccines, with an Army doctor testifying that she is examining 2,544 unverified deaths reported to HHS's Vaccine Adverse Event Reporting System. Army doctor Theresa Long, who is board certified in aerospace medicine, said during a Virginia federal court hearing that she is aware of 28 individuals who died due to COVID vaccinations but was barred from sharing further details. The deaths under scrutiny are linked to mRNA vaccines from Pfizer/BioNTech and Moderna. Long, who began her duties at the Defense Department 10 days before she was set to retire, expects to finish her work within a year. The Pentagon said it has nothing to announce at this time, referring to a statement on reinstating service members discharged during the Biden administration for refusing the shots.
BioNTech halts cancer vaccine trial, Arcturus and Moderna fall
Messenger RNA drug developers Arcturus Therapeutics and Moderna traded lower on Friday after BioNTech halted a mid-stage trial for its mRNA-based cancer vaccine BNT122, developed with Roche, due to efficacy concerns. Arcturus lost more than 7%, while Moderna fell for a third consecutive session, weighed down by the trial setback and a new $2.6B convertible note offering. Last week, Moderna shares had climbed to a post-pandemic peak after a late-stage trial win for its own mRNA cancer shot, Intismeran, developed with Merck. BioNTech's BNT122-01 study enrolled patients with surgically removed colorectal cancers, whereas Moderna's Phase 3 INTerpath-001 trial targeted resected melanoma. BioNTech said it discontinued the trial after a data safety monitoring board noted a numerical imbalance in overall survival between treatment arms, determining the trial was unlikely to reach its efficacy outcome. Scotiabank analyst Louise Chen argued the decision bodes well for Merck, while BMO Capital Markets analyst Evan David Seigerman called it a clear setback but noted the negative read-through is not necessarily one-to-one across indications.
Pfizer won FDA approval Thursday for its updated Comirnaty COVID vaccine, with deliveries starting immediately and doses expected in pharmacies and clinics within days. The vaccine, developed with BioNTech, is now limited to adults 65 and older and higher-risk patients aged 5 to 64, a much smaller market than the pandemic-era rollout. Comirnaty has distributed over five billion doses worldwide, but the new seasonal demand is uncertain. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine. Shares traded at $27.9079 on August 28, 5.27% above the GF Value estimate of $26.51, indicating a premium before uptake and reimbursement details emerge.
BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails
BioNTech shares tumbled 8% to $102.38 after the company terminated its Phase 2 colorectal cancer vaccine trial for futility, a setback that also dragged Moderna down 6% to $134.48 while Pfizer held nearly flat at $27.91. The trial, BNT122-01, tested the mRNA vaccine autogene cevumeran as a monotherapy in high-risk Stage II/III colorectal cancer patients, and an independent Data Safety Monitoring Board found a numerical imbalance in overall survival that made further continuation futile. The futility boundary was first crossed in October 2025, but the data were initially deemed too immature to halt the study. Moderna's recent melanoma vaccine success does not shield it from the read-across because colorectal cancer is immunologically cold, and BioNTech's monotherapy design was a harder hurdle than Moderna's checkpoint-combination approach. Separately, the FDA approved the 2026-2027 COVID-19 vaccine formula from Pfizer and BioNTech, but that seasonal approval is not enough to offset the loss of a flagship oncology asset for BioNTech, which still holds €16.6 billion in cash and securities.
Pfizer Vaccine Milestones Could Shift Investment Narrative
Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. These milestones highlight Pfizer's role in infectious disease prevention, with the Lyme vaccine potentially becoming a key proof point for its pipeline. However, unresolved legal and pricing pressures, including the Depo Provera settlement program, remain overhangs. Pfizer's narrative projects $54.9 billion in revenue and $9.2 billion in earnings by 2029, implying a 4.6% yearly revenue decline and a $1.7 billion earnings increase from $7.5 billion today, yielding a $29.19 fair value, a 4% upside to its current price. Some analysts assume revenue could fall to about US$50.6 billion by 2029, reinforcing concerns that pipeline wins may not fully offset pricing pressure and patent losses.
Pfizer and BioNTech Win FDA Approval for Updated COVID-19 Shot
Pfizer and BioNTech have received U.S. FDA approval for their updated mRNA COVID-19 vaccine, COMIRNATY XFG, for the 2026-27 season. The shot targets the XFG variant and is indicated for individuals aged five to 64 with at least one underlying condition that puts them at high risk for severe outcomes from the virus, as well as for all adults aged 65 and older.
Merck and Moderna Cancer Vaccine Success Lifts Five Biotech Stocks
Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.
22UA.XETRA · Technology · Positive BioNTech surged 21.6% on read-across excitement from Merck and Moderna's positive Phase 3 cancer vaccine results, which validate the mRNA technology platform.
ILMN · Demand · Positive Illumina's NovaSeq X sequencers are required for every individualized neoantigen dose, driving demand for its sequencing platforms.
PACB · Demand · Positive Pacific Biosciences gained 5.8% on read-across excitement from the cancer vaccine success, though no specific company development was mentioned.
DHR · Demand · Positive Danaher saw mid-teens bioprocessing order growth in Q2, indicating strong demand for its bioprocessing products.
Moderna and Merck announced that their personalized mRNA cancer therapy intismeran autogene, combined with Keytruda, met its primary endpoint of recurrence-free survival in a late-stage melanoma study. The INTerpath-001 trial also met the secondary goal of distant metastasis-free survival in patients with high-risk Stage IIB-IV melanoma after surgery. The companies are testing intismeran in nine additional phase II and III studies across lung, bladder, and kidney cancers. Moderna sees the result as validation of its mRNA platform beyond infectious-disease vaccines, though it still faces competition from BioNTech and others, and its stock trades at a premium with a Zacks Rank of 3, or Hold.
BioNTech Presents First-in-Class Pumitamig Plus B7H3 ADC Lung Cancer Data
BioNTech SE has already presented new clinical data from its broad lung cancer pipeline at the 2026 IASLC World Conference on Lung Cancer in Seoul, covering key assets pumitamig, gotistobart and several mRNA-based immunotherapy approaches. The company's first-in-class combination data pairing its PD-(L)1 x VEGF bispecific antibody pumitamig with a B7H3-targeted antibody-drug conjugate underscores BioNTech's push into differentiated, novel-novel immunotherapy regimens in lung cancer. The new WCLC lung cancer data reinforces that pivot but does not, by itself, change the near term reality that BioNTech is unprofitable, dependent on pipeline progress, and exposed to the risk that key late stage trials fail to convert into meaningful non COVID revenue. Among recent developments, the May 30 ROSETTA Lung program update on pumitamig stands out alongside the new pumitamig plus B7H3 ADC data, framing a clearer near term catalyst path in lung cancer around multiple Phase 3 readouts. BioNTech's narrative projects €2.2 billion revenue and €374.5 million earnings by 2029, while the most pessimistic analysts once modeled a 25.6% annual drop to about €1.1 billion by 2029.
Moderna and Merck Report First Phase III Win for mRNA Cancer Therapy
Moderna and Merck announced positive phase III results for their personalized mRNA cancer therapy intismeran autogene in high-risk melanoma, sending Moderna shares up 177% and adding more than $44 billion to its market capitalization. The INTerpath-001 study met its primary endpoint of recurrence-free survival and a key secondary goal of distant metastasis-free survival in patients treated with intismeran plus Merck's Keytruda, though no specific numbers were disclosed. The companies said the results represent the first positive phase III readout for an individualized neoantigen therapy and an mRNA-based cancer therapy, and they plan to engage with regulators on potential filings. Merck shares closed about 13% higher, while BioNTech rose 22% as investors saw validation for mRNA oncology platforms. Moderna and Merck are testing intismeran across nine phase II and phase III studies in other cancers including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
Moderna and Merck Post First Successful Late-Stage mRNA Cancer Vaccine Trial
Moderna and Merck announced positive Phase 3 results for an individualized mRNA cancer vaccine, marking the first successful late-stage trial of its kind. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. Elon Musk said mRNA technology could fundamentally change how diseases are treated, making medicine more of a software problem than a biological one. Moderna shares skyrocketed 176.97% to close at $174.38, while Merck closed 12.6% higher at $152.20. BioNTech gained 21.96% and Arcturus Therapeutics closed 25.21% higher as peers rallied on the news.
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
MRNA · Technology · Positive Moderna's individualized mRNA cancer vaccine succeeded in Phase 3, leading to a 176.97% surge in its shares.
MRK · Technology · Positive Merck's Keytruda combined with the mRNA vaccine showed significant improvement in melanoma patients, and Merck shares rose 12.6%.
22UA.XETRA · Technology · Positive BioNTech gained 21.96% as a peer in the mRNA space, benefiting from the positive trial news.
ARCT · Technology · Positive Peers rallied on the positive mRNA cancer vaccine trial results, indicating sector-wide validation.
Biotech stocks hit post-pandemic high after Moderna, Merck mRNA cancer trial win
Biotech stocks reached their highest level since the height of the pandemic after Moderna and Merck announced that a late-stage trial testing their messenger RNA-based cancer therapy met its main goals. Healthcare became the best-performing sector in the S&P 500, with the State Street SPDR S&P Biotech ETF adding more than 4% to reach its highest level since February 2021. The individualized neoantigen therapy intismeran autogene, combined with Merck's Keytruda, improved recurrence-free survival with a statistically significant and clinically meaningful effect in the Phase 3 INTerpath-001 trial. Moderna shares more than doubled, Merck added over 12%, and rival vaccine makers BioNTech and Novavax also gained sharply. Gene editing companies including Prime Medicine, Intellia, CRISPR, Editas Medicine, and Beam Therapeutics were notable gainers, while AI-related biotechs Absci and Recursion Pharmaceuticals rallied after Anthropic selected Twist Bioscience as an independent evaluator.
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▲Competition
Artificial Intelligence › AI Applications & Copilots ▲Technology
Biotech & Genomic Medicine › Gene & Cell Editing ▲Competition
Biotech & Genomic Medicine › AI Drug Discovery ▲Competition
MRNA · Technology · Positive Moderna's mRNA cancer therapy met main goals in Phase 3 trial, leading to shares more than doubling.
MRK · Technology · Positive Merck's Keytruda combined with Moderna's mRNA cancer therapy met main goals in Phase 3 trial, boosting Merck's oncology pipeline.
TWST · Demand · Positive Anthropic selected Twist Bioscience as independent evaluator, indicating demand for its services.
22UA.XETRA · Competition · Positive Rival vaccine makers gained sharply as sector rallied on Moderna's success, but no specific development for BioNTech.
NVAX · Competition · Positive Novavax gained sharply as part of sector rally, but no company-specific news.
Moderna shares double on promising cancer vaccine data
Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock. The vaccine, intismeran, reduced the risk of recurrence and spread of skin cancer when combined with Merck's blockbuster immunotherapy drug Keytruda in a late-stage trial. Leerink Partners analysts now expect about $1.4 billion sales potential for the therapy by 2032, up from their previous projection of up to $1.2 billion. Short sellers faced record one-day losses, with short interest at 13.5% of the free float, according to ORTEX. The Nasdaq biotech index rose 4.4% to a fresh record high, while BioNTech climbed 20% and Novavax rose 6%.
Arbutus receives $178 million from Moderna settlement and plans up to $230 million shareholder return
Arbutus Biopharma reported second quarter 2026 financial results and announced it received a first payment of approximately $178 million in July from its $950 million settlement with Moderna, and expects to return up to approximately $230 million to shareholders through share repurchases starting in the third quarter. The company also filed three international patent infringement lawsuits against Pfizer and BioNTech related to its lipid nanoparticle technology, and achieved alignment with the FDA on a Phase 2b clinical trial design for its chronic hepatitis B drug candidate imdusiran. As of June 30, 2026, Arbutus held cash, cash equivalents and marketable securities of $92.6 million, and reported a net loss of $5.1 million for the quarter.
Pfizer raises 2026 revenue guidance while BioNTech cuts forecast and announces CEO transition
Pfizer raised its full-year 2026 revenue guidance by $500 million to a range of $60.5 billion to $62.5 billion, while BioNTech cut its full-year 2026 revenue guidance to €1.6 billion to €1.9 billion from a prior range of €2.0 billion to €2.3 billion and announced that co-founder and CEO Prof. Ugur Sahin will step down to lead a new independent entity, with Guido Oelkers succeeding him as CEO by February 1, 2027. Pfizer reported Q2 2026 revenues of $15.0 billion, a 1% operational increase year-over-year, and adjusted diluted earnings per share of $0.77, while BioNTech's Q2 2026 revenues fell 59.5% year-over-year to €105.6 million and its IFRS net loss widened to €820.8 million. The European Commission authorized the companies' updated XFG-adapted COVID-19 vaccine on July 29. Pfizer also announced an expansion of productivity initiatives expected to yield $2.5 billion in additional savings between 2027 and 2029, while BioNTech maintains €16.6 billion in cash, cash equivalents, and security investments to fund its oncology pipeline.
BioNTech Appoints Guido Oelkers as CEO, Succeeding Co-Founder Ugur Sahin
BioNTech has appointed Guido Oelkers as its new Chief Executive Officer, effective February 1, 2027, succeeding co-founder and current CEO Ugur Sahin. Oelkers brings more than three decades of biotechnology and pharmaceutical industry experience, having served as CEO of Swedish Orphan Biovitrum AB since 2017 and previously holding CEO roles at BSN Medical Holding GmbH, Gambro AB, and Invida Holdings. The leadership transition also involves Chief Medical Officer Özlem Türeci, who intends to leave her role to lead a new independent company alongside Sahin, while the search for a new CMO is ongoing. BioNTech shares closed at $90.58 on Friday, down 2.44%, and rose 1.67% in pre-market trading to $92.09.
Pfizer and BioNTech Win EU Approval for XFG-Adapted COVID-19 Vaccine
Pfizer and BioNTech have secured European Commission marketing authorisation for their COVID-19 vaccine formulation targeting the XFG variant. The approval covers active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older, and is valid in all 27 European Union Member States plus Iceland, Liechtenstein and Norway. The decision follows a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use in July 2026, based on guidance from the agency’s Emergency Task Force to update vaccines against the XFG variant. The companies have already begun at-risk manufacturing of the monovalent XFG-adapted vaccine to ensure supply readiness ahead of the respiratory disease season, and have submitted data to other regulatory authorities.
Head and Neck Squamous Cell Carcinoma Market to Grow at 10.5% CAGR Through 2036 on Novel Immunotherapies
The head and neck squamous cell carcinoma market is projected to grow at a compound annual growth rate of 10.5% during the 2026 to 2036 forecast period, driven by the launch of emerging novel immunotherapies. The market size across the seven major markets—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was valued at USD 850 million in 2025, with the United States accounting for the largest share. Key therapies in development include Amivantamab from Johnson & Johnson, BNT113 from BioNTech, Petosemtamab from Genmab, and Eftilagimod Alfa from Immutep, among others. The total incident cases of head and neck squamous cell carcinoma in the seven major markets were approximately 153,500 in 2025. KEYTRUDA generated the highest revenue among all therapies for the disease in the United States that year.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
22UA.XETRA · Technology · Positive BNT113 from BioNTech is listed as a key therapy in development for head and neck squamous cell carcinoma, driving market growth.
GMAB · Technology · Positive Petosemtamab from Genmab is listed as a key therapy in development for head and neck squamous cell carcinoma, driving market growth.
JNJ · Technology · Positive Amivantamab from Johnson & Johnson is listed as a key therapy in development for head and neck squamous cell carcinoma, driving market growth.
Pfizer Faces New International Patent Lawsuits Over COVID-19 Vaccine
Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines, extending the legal dispute beyond the existing U.S. litigation into Canada and several European countries under the Unified Patent Court. The lawsuits seek monetary damages and permanent injunctions that could, in a worst-case scenario, affect Pfizer's ability to sell the vaccines in some markets. The dispute centers on lipid nanoparticle technology used in mRNA delivery, adding legal and operational risks to Pfizer's key vaccine franchise. Pfizer's stock last closed at $25.05, with a 10.5% gain over the past year but declines of 19.5% over three years and 22.6% over five years. The legal process is typically lengthy, giving Pfizer time to pursue defenses or settlements, but investors now face another potential source of cash outflows and operational constraints.
PFE · Regulation · Negative Pfizer faces new patent lawsuits in Canada and Europe over its COVID-19 vaccine, risking injunctions and cash outflows.
ABUS · Competition · Positive Arbutus and Genevant filed patent lawsuits against Pfizer/BioNTech, potentially strengthening their IP position and licensing prospects.
Genevant Sciences · Competition · Positive Genevant, co-plaintiff with Arbutus, filed lawsuits that could strengthen its patent position and lead to licensing revenue.
22UA.XETRA · Regulation · Negative BioNTech, as co-defendant with Pfizer, faces patent lawsuits that could affect its vaccine franchise.
Tuberculosis Pipeline Features Over 30 Drugs in Development from 28-Plus Companies
A new report from DelveInsight reveals that more than 28 companies are actively developing over 30 pipeline drugs for tuberculosis. Key players include Biofabri, Otsuka Pharmaceutical, GlaxoSmithKline, Archivel Farma, BioNTech, CanSino Biologics Inc., Medincell, and others, with promising therapies such as MTBVAC, Quabodepistat, GSK3036656, RUTI, BNT164, and Ad5-105K in various clinical stages. Approximately four-plus drugs are in late-stage development, and notable mechanisms of action include leucyl-tRNA synthetase inhibitors, immunostimulants, and DprE1 protein inhibitors. The report also highlights recent milestones, including the first patient dosed in a Phase IIb trial of alpibectir-ethionamide in March 2026 and the initiation of a new cohort in the IMAGINE trial of MTBVAC in February 2026.
Global Vaccine Sales Market to Reach US$141.40 Billion by 2036
The global vaccine sales market is projected to grow from US$76.40 billion in 2026 to US$141.40 billion by 2036, expanding at a compound annual growth rate of 6.3%. Growth is supported by rising infectious disease prevalence, broader government-funded immunisation programmes in low- and middle-income countries, and sustained investment in mRNA, viral vector, DNA and needle-free vaccine technologies. Platform-based technologies are enabling developers to pursue multiple disease targets, with programmes such as Moderna and Merck's mRNA-4157 illustrating the expanding role of mRNA in oncology. In December 2025, the Coalition for Epidemic Preparedness Innovations committed up to US$54.3 million to support a Phase III trial of Moderna's mRNA-based H5 pandemic influenza vaccine candidate, advancing the first mRNA influenza vaccine into pivotal-stage development. The market remains sensitive to U.S. tariff policies and supply-chain pressures, prompting companies to localise manufacturing and diversify suppliers. Key players include GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca and Serum Institute of India, with the report profiling 21 companies in total.
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▲Demand
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
MRNA · Technology · Positive CEPI funding for Phase III trial of Moderna's mRNA pandemic influenza vaccine and mention of mRNA-4157 oncology program.
22UA.XETRA · Demand · Positive Market growth and mRNA oncology programs like mRNA-4157 (with Merck) boost demand for BioNTech's mRNA platform.
SAN.PA · Demand · Positive Market growth and government immunisation programmes increase demand for Sanofi's vaccines.
Serum Institute of India · Demand · Positive Market growth and government-funded programmes in low- and middle-income countries benefit Serum Institute's vaccine sales.
AZN.LSE · Demand · Positive Market growth benefits AstraZeneca's vaccine sales, though no specific company news.
GSK.LSE · Demand · Positive Market growth benefits GSK's vaccine sales, though no specific company news.
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock
Cathie Wood's Ark Invest sold over 122,000 shares of BioNTech across two days in early July, a transaction valued at around $7.4 million. The sales left the Ark Genomic Revolution ETF with just 307 shares, making BioNTech the smallest holding in the fund. The divestment comes as BioNTech faces declining revenue from its COVID-19 vaccine, back-to-back net losses in 2024 and 2025, and the upcoming departure of its co-founders. The company is shifting focus to oncology treatments but has only one commercial product.
22UA.XETRA · Capital · Negative Ark Invest sold most of its BioNTech holdings, and the company faces declining vaccine revenue, net losses, and co-founder departures.
ARK Investment Management LLC · Capital · Neutral Ark Invest is the seller, but the news is about its portfolio move, not a direct impact on the firm itself.
Head and Neck Squamous Cell Carcinoma Market to Grow at 10.5% CAGR Through 2036 on Novel Immunotherapies
The head and neck squamous cell carcinoma market is projected to grow at a compound annual growth rate of 10.5% during the 2026–2036 forecast period, driven by the launch of emerging novel immunotherapies. The market size across the seven major markets—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was estimated at USD 850 million in 2025, with the United States accounting for the largest share. Key therapies in development include Amivantamab from Johnson & Johnson, BNT113 from BioNTech, CUE-101 from Cue Biopharma, Petosemtamab from Genmab, and Eftilagimod Alfa from Immutep, among others. The total incident cases of head and neck squamous cell carcinoma in the seven major markets were approximately 153,500 in 2025. Growth is further supported by rising cancer incidence, increasing adoption of immunotherapies and targeted therapies, and a robust pipeline of investigational drugs.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Demand
CUE · Demand · Positive Cue Biopharma's CUE-101 is listed as a key therapy in development for head and neck squamous cell carcinoma, and the market growth driven by novel immunotherapies directly benefits its potential adoption.
22UA.XETRA · Demand · Positive BioNTech's BNT113 is mentioned as a key therapy in development for head and neck squamous cell carcinoma, and the market growth driven by novel immunotherapies supports its prospects.
GMAB · Demand · Positive Genmab's Petosemtamab is listed as a key therapy in development for head and neck squamous cell carcinoma, and the market growth driven by novel immunotherapies benefits its potential.
JNJ · Demand · Positive Johnson & Johnson's Amivantamab is mentioned as a key therapy in development for head and neck squamous cell carcinoma, and the market growth driven by novel immunotherapies supports its commercial prospects.
In Silico Protein Design Market to Reach $4.86 Billion by 2030
The in silico protein design market is projected to grow from $1.87 billion in 2025 to $4.86 billion in 2030, at a compound annual growth rate of 20.9%. Key drivers include advances in computational biology, increased availability of protein structure databases, and expanding use in drug discovery and personalized medicine. Major trends shaping the market are AI-driven protein modeling platforms, cloud-based simulation software, machine learning integration in structure prediction, and computational enzyme engineering. In July 2023, BioNTech SE acquired InstaDeep Ltd. to combine immunotherapy with advanced AI and machine learning for accelerated drug discovery. North America was the largest region in 2025, while Asia-Pacific is expected to be the fastest-growing region.
Biotech & Genomic Medicine › AI Drug Discovery ▲Technology
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
22UA.XETRA · Technology · Positive BioNTech's acquisition of InstaDeep in July 2023 is highlighted as a key trend, combining AI with immunotherapy for drug discovery, which aligns with market growth drivers.
BioNTech reportedly held buyer talks over plans to exit German sites
BioNTech has held confidential discussions with prospective bidders regarding plans to shutter manufacturing locations in Germany, Handelsblatt reported. The company announced with its first-quarter 2026 results that it would exit its German manufacturing sites in Idar-Oberstein, Marburg, and Tübingen by the end of this year as part of a restructuring to optimize global production capacity. It also plans to exit its unprofitable unit JPT Peptide in Berlin by year-end, with a search for a new peptide supplier already underway. The divestments come as BioNTech grapples with a sharp revenue decline, from 21.6 billion dollars in 2021 to 3.4 billion dollars in 2025, due to plummeting demand for its Comirnaty COVID-19 vaccine developed with Pfizer.
Arcus Biosciences and Bristol-Myers Squibb to Test Casdatifan with Pumitamig in Kidney Cancer Trial
Arcus Biosciences announced a clinical trial collaboration with Bristol-Myers Squibb to add its investigational kidney cancer drug casdatifan to Bristol-Myers's ongoing Phase 1/2 ROSETTA RCC-208 trial. The trial is evaluating pumitamig, an investigational bispecific antibody jointly developed by BioNTech and Bristol Myers Squibb for advanced renal cell carcinoma. Arcus will supply casdatifan for two new treatment arms added to the existing trial structure, with both companies retaining full development and commercial rights to their respective drugs. Arcus CEO Terry Rosen stated the collaboration is a top priority to potentially deliver an additional effective TKI-free option in the first-line setting.
Biotech & Genomic Medicine › Oncology Therapeutics Competition
RCUS · Technology · Positive Arcus's casdatifan is being added to a Phase 1/2 trial, advancing its clinical development in kidney cancer.
BMY · Technology · Positive Bristol-Myers gains access to Arcus's casdatifan for its ongoing pumitamig trial, potentially strengthening its kidney cancer pipeline.
22UA.XETRA · Technology · Positive BioNTech's jointly developed pumitamig is being tested in combination with casdatifan, potentially expanding its therapeutic use.
mRNA Cancer Vaccine Market to Surpass $1.20 Billion in 2026, Report Finds
The global mRNA cancer vaccine market is projected to exceed US$1.20 billion by 2026, according to a new report from ResearchAndMarkets.com. The market is expected to see continued robust growth through 2036, driven by advances in precision oncology, sequencing technologies, and an expanding pipeline of clinical candidates. Key players such as BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing platform and clinical innovations, while innovations like self-amplifying mRNA constructs and improved lipid nanoparticle delivery systems are enhancing scalability. The report also highlights that production relies on globally sourced inputs like lipid nanoparticles and nucleotides, making supply chains vulnerable to tariffs and disruptions, which could impact costs and development timelines. The analysis covers market segmentation by vaccine type, therapeutic approach, clinical phase, indication, and end-user across regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Legend Biotech and BioNTech Seen as Potential Takeover Targets
Legend Biotech and BioNTech are emerging as potential acquisition targets amid a surge in pharmaceutical dealmaking. The sector saw over $65 billion in mergers and acquisitions in the first quarter, the best since 2020, with 16 deals of at least $1 billion each. Legend Biotech’s Carvykti therapy for multiple myeloma generated $597 million in first-quarter sales, up 62% year over year, and partner Johnson & Johnson projects peak annual sales above $5 billion. The company also reported a 100% objective response rate in phase 1 data for its next-generation in vivo CAR-T therapy and has a 99% manufacturing success rate. BioNTech holds 16.8 billion euros in cash and investments, offsetting a large portion of any purchase price, and has more than 25 phase 2 and phase 3 trials, including six late-stage readouts expected this year. Co-founders Uğur Şahin and Özlem Türeci plan to transition out of management by the end of 2026, potentially opening the door to a buyout. Both stocks have fallen more than 13% over the past year, and neither company is profitable.
Four Public Companies Helping Lead a New Era in Cancer Treatment
Cancer treatment is undergoing a major transformation as a new generation of biotechnology companies develops smarter, more targeted therapies. BioNTech, known for its COVID-19 vaccine, has expanded into oncology with mRNA cancer vaccines and personalized immunotherapies. Summit Therapeutics has seen success with ivonescimab, a novel immunotherapy for lung cancer. CG Oncology is working on an oncolytic immunotherapy platform for bladder cancer. NeOnc Technologies is developing targeted oncology therapies for significant unmet medical needs. These four companies represent different facets of a broader movement toward more personalized and innovative cancer care.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Technology
22UA.XETRA · Technology · Positive BioNTech's expansion into mRNA cancer vaccines and personalized immunotherapies is highlighted as leading a new era in cancer treatment.
CGON · Technology · Positive CG Oncology's oncolytic immunotherapy platform for bladder cancer is highlighted as part of a new era in cancer treatment.
NTHI · Technology · Positive NeOnc Technologies' targeted oncology therapies for unmet medical needs are featured as innovative cancer care.
Moderna eyes acquiring BioNTech's German plants set for closure
Moderna is exploring investments in German manufacturing facilities and is particularly interested in acquiring sites that BioNTech plans to shut down as part of its restructuring, CEO Stephane Bancel told Handelsblatt. Bancel said the facilities would be an interesting option compared with building a new one if the right partnership with the German government is found. BioNTech announced in May it would close several manufacturing sites in Germany and Singapore, affecting up to 1,860 jobs, amid declining COVID-19 vaccine demand, with facilities in Idar-Oberstein, Marburg and Tuebingen set to shut by the end of 2027 while divestment options are explored.
Germany
